Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Lancet (London, England)(2023)
摘要
Eli Lilly and Company.
更多查看译文
关键词
oral orforglipron,diabetes,dose-response
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要